Industry News
Pharmaceutical Industry News

GSK is consolidating two of its…
GSK is consolidating two of its influenza vaccine manufacturing sites into one, leaving hundreds of jobs at risk.
As Novo Nordisk continues its epic…
As Novo Nordisk continues its epic battle with Eli Lilly for market share in the increasingly competitive obesity and diabetes space, Novo is launching a major rebranding of its business, its logo and its name.
Healthcare marketing and comms…
Healthcare marketing and comms agency, Deerfield Group, is creating a new model for growth while making a series of appointments and promotions to help bolster its plans.
GSK is advancing its inaugural…
GSK is advancing its inaugural lung cancer asset, Jideytro, toward a landmark first-line FDA approval, aided by an unprecedented complete response rate.
Etcamah now joins Roche’s rival…
Etcamah now joins Roche’s rival oral SERD, giredestrant, in missing the mark in first-line HR+/HER2- breast cancer, spelling trouble for others’ efforts in the same setting.
How Did a Heart Drug With So Much Promise Fall So Flat?
Cardiologists are struggling to figure out why a drug that should have prevented heart attacks didn’t work at all.
Newly revealed global phase 3 data…
Newly revealed global phase 3 data from Merck and Gilead’s failed Trodelvy first-line non-small cell lung cancer trial could reignite the question around translating Chinese data to the West.
Following formal sign-off from the…
Following formal sign-off from the FDA, Handa Pharmaceuticals’ branded drug reformulation strategy has paid off for a third time.
A preliminary 15% higher death…
A preliminary 15% higher death risk in a phase 3 trial threatens to thwart AstraZeneca and Daiichi Sankyo’s bid to establish their star ADC Enhertu as a first-line treatment for patients with HER2-mutant non-small cell
Takeda’s long-time R&D chief…
Takeda's long-time R&D chief Andy Plump will retire. Daiichi Sankyo beat back a $1.3 billion damage claim in a lawsuit. Samsung Biologics signed a $262 million contract with an unnamed client. And more.
Argonaut Manufacturing Services, a…
Argonaut Manufacturing Services, a CDMO specializing in aseptic fill-finish for injectable biologics and other drugs, has sold its life sciences and diagnostics unit to the private equity firm 1315 Capital for an undisclosed price.
In his first interview after…
In his first interview after taking the reins of the FDA’s Oncology Center of Excellence, Angelo de Claro, M.D., is outlining a regulatory agenda that prioritizes organizational strength and continued regulatory modernization.
Commercial plans can no longer be…
Commercial plans can no longer be static. Acumetis' Swathi Rangan explains how teams can adapt strategy as markets evolve.
Real-world data has become table…
Real-world data has become table stakes. The next challenge is connecting it to genetic insight that can sharpen R&D decisions.
Lonza’s plans for a new…
Lonza's plans for a new spray-drying facility in Bend, Oregon, affirm the company's commitment both to high-margin medicines and the U.S. At the same time, fellow Swiss CDMO CordenPharma is also making expansion moves, albeit
With positive phase 3 results in…
With positive phase 3 results in hand, AbbVie is one step closer to expanding the reach of its key migraine preventative Qulipta, also known as atogepant.
In a move that at least one local…
In a move that at least one local HIV charity has deemed “profoundly disappointing,” England's health technology assessor NICE is currently recommending against coverage of Gilead Sciences’ landmark twice-a-year PrEP medication lenacapavir on the National
Novartis’ recent dual clinical…
Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board’s oversight of dealmaking.
As Samsung Biologics works to…
As Samsung Biologics works to close a massive buyout to branch out into peptides, the Korean CDMO’s bread-and-butter contracting work continues to gin up big-ticket contracts from the drug industry.
A New Drug Lifts the Fog of Sleepiness for Those With Narcolepsy
The first-of-its-kind drug offers a reprieve for people who live with the debilitating sleep disorder.


